CAN Spotlight: Paddle Party for a Purpose
The 2nd Annual Paddle Party for a Purpose sold out at Exmoor Country Club, with Team Ryan O’Connor raising money and awareness for Angelman syndrome through paddle, dinner, and live music.
CAN Spotlight: 2nd Annual Hole Out Fore Heath Golf Tournament
The Second Annual Hole Out Fore Heath Golf Tournament brought together 120 golfers in Florida, raising funds for Angelman syndrome research alongside a silent auction and raffles.
RSVP for the January 2025 EL-PFDD Meeting
FAST and ASF will co-host a virtual Externally Led-PFDD Meeting on January 29, 2025, giving the Angelman syndrome community a direct voice with the FDA on therapy development.
FAST and ASF Announce their Partnership with the Institute for Gene Therapies
ASF and FAST partner with the Institute for Gene Therapies to push for policy changes that ensure patients can access cutting-edge gene therapies for Angelman syndrome.
2024 Global Science Summit Recap
The 17th Global Science Summit gathered over 1,000 attendees from 55 countries, spotlighting major progress across FAST’s research pillars and multiple advancing clinical trials.
Ionis Pharmaceuticals releases information on their planned phase 3 clinical trial for Angelman syndrome
Ionis Pharmaceuticals announces ION582 will advance into Phase 3, called REVEAL, with details to be presented at the FAST Global Science Summit on November 9th.
The PFDD Survey is now open
The EL-PFDD Survey is now open, inviting parents and caregivers to share their experiences with Angelman syndrome to help shape the January 2025 FDA discussion.
CAN Spotlight: Remi Cup 2024
In its 3rd year, the Remi Cup golf tournament drew 104 golfers to Oklahoma, raising over $30,000 for FAST as the Matheson family continues advocating for daughter Remi.
FAST announces establishment of associated drug development accelerator AS²Bio
FAST launches AS²Bio, a drug development accelerator building an integrated ecosystem to advance gene therapy, CRISPR, and stem cell programs for Angelman syndrome and beyond.